Investors don’t often equate the growth of biotech stocks with dividends, but the reality is, many of the largest pharmaceuticals and the sector’s elder statesmen offer huge revenue streams and dividend income potential. This includes our latest Best Dividend Stocks Model Portfolio pick.
After years of advancement and a few well-timed buyouts, our latest pick features a vast portfolio of biotech blockbusters under its umbrella. From new oncology medicines to a robust cardiovascular portfolio, our pick is highly profitable with cash flow margins north of 40%. This allows it to generate strong current dividends, a robust yield of 3.5% and a history of hefty share buybacks.
Our new pick’s pipeline is chock full of potential, and includes over 50 different drugs in various stages of development covering over 40 distinct disease areas. This provides plenty of runway for the firm to successfully launch future blockbusters and continue on its swift pace of revenue growth.
You can check out the Best Dividend Stocks Model Portfolio to explore all the stocks.
